迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688062 迈威生物

已收盘 12-23 15:00:00

{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":20.69,"timestamp":1734937200000,"preClose":20.83,"halted":0,"volume":2818762,"delay":0,"floatShares":204000000,"shares":400000000,"eps":-2.6883,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.14,"latestTime":"12-23 15:00:00","open":20.83,"high":21.18,"low":20.47,"amount":58692400,"amplitude":0.0341,"askPrice":20.7,"askSize":55,"bidPrice":20.69,"bidSize":7,"shortable":0,"etf":0,"ttmEps":-2.6883,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":20.83,"symbolType":"stock_kcb","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":22.91,"lowLimit":18.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":399600000,"pbRate":4.31,"roa":"--","roe":"--","epsLYR":-2.64,"committee":0.17551,"marketValue":8268000000,"floatMarketCap":4224000000,"peRate":-7.696314,"changeRate":-0.0067,"turnoverRate":0.0138,"status":1,"afterMarket":{"amount":0,"volume":0,"close":20.69,"buyVolume":0,"sellVolume":0,"time":1734939238975,"indexStatus":"已收盘 12-23 15:30:00","preClose":20.83}},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2493753884","title":"“烧钱”不止  迈威生物拟赴港二次上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2493753884","media":"中国经营报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493753884?lang=zh_cn&edition=full","pubTime":"2024-12-21 03:46","pubTimestamp":1734723960,"startTime":"0","endTime":"0","summary":"自迈威生物宣布筹划赴港上市后，有投资者在互动平台上不断感慨道。12月15日晚间，迈威生物公告召开董事会、监事会会议，审议通过关于公司发行H股股票并在香港联交所上市等相关议案。迈威生物方面称，公司拟发行H股并上市，将在股东大会决议有效期内选择适当的时机和发行窗口完成。自A股上市以来，迈威生物已有三款产品陆续获批上市并推进至商业化阶段。此后两年，迈威生物每年分别有1款产品获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-21/doc-ineaecqf5395156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2492344851","title":"迈威生物收盘下跌0.24%，最新市净率4.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2492344851","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492344851?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:41","pubTimestamp":1734698519,"startTime":"0","endTime":"0","summary":"12月20日，迈威生物今日收盘20.83元，下跌0.24%，最新市净率4.34。消息面上，迈威生物11月5日接待东方证券等69家机构调研，上市公司接待人员包括董事、高级副总裁、董事会秘书胡会国,投资者关系副总监王静。迈威(上海)生物科技股份有限公司是一家创新型生物制药企业，主营业务为治疗用生物制品的研发、生产与销售，主要产品为抗体药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220204531ab871f9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220204531ab871f9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2492480210","title":"多家上市公司启动 “A+H”上市进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2492480210","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492480210?lang=zh_cn&edition=full","pubTime":"2024-12-20 06:22","pubTimestamp":1734646948,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0076","BK0028","159982","BK0239","LU1064131003.USD","BK0214","600276","BK0012","BK0065","BK0188","600699","LU1064130708.USD","BK0187","BK0264","BK0061","LU2488822045.USD","LU1328615791.USD","BK0060","BK0196","LU2148510915.USD","BK0183","688062","BK0130","LU0405327148.USD","LU0405327494.USD","399300"],"gpt_icon":0},{"id":"2492512637","title":"【投融资动态】重庆迈威生物战略融资，投资方为中新基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2492512637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492512637?lang=zh_cn&edition=full","pubTime":"2024-12-19 19:30","pubTimestamp":1734607824,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于12月15日公布的信息整理，迈威（重庆）生物医药有限公司战略融资，融资额未披露，参与投资的机构包括中新基金。重庆迈威生物是一家成立于2024年5月23日的骨健康创新药研发商，主要从事药品批发、药品生产、药品零售、药品委托生产及药品进出口等业务。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900033096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2492394955","title":"上市多年仍未盈利 资金压力增大！迈威生物布局“A+H”","url":"https://stock-news.laohu8.com/highlight/detail?id=2492394955","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492394955?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:54","pubTimestamp":1734432898,"startTime":"0","endTime":"0","summary":"另一方面，迈威生物上市三年来，仍然处于亏损的局面，从2022年至今年前三季度，其亏损合计超27亿元。截至今年三季度末，公司货币资金余额仅15.98亿元。扩大合作另一方面，境外上市也将进一步加速迈威生物的国际化步伐。文章来源：21世纪经济报道上市多年仍未盈利，资金压力增大！迈威生物布局“A+H”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217190910a1f59f71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217190910a1f59f71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2492963283","title":"A股融资34亿、分红0，迈威生物拟赴港二次上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2492963283","media":"尺度商业","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492963283?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:13","pubTimestamp":1734430416,"startTime":"0","endTime":"0","summary":"文 | 杨万里12月16日、17日，迈威生物两个交易日合计下跌7.53%。近日，迈威生物宣布计划发行H股股票并在香港联交所上市。12月15日晚，迈威生物公告称，为满足经营发展的资金需求，实现可持续发展，提升国际化水平，拟发行H股并在香港联交所主板上市。在资金方面，迈威生物于2022年1月份上市。目前，迈威生物未实现正盈利。2024年前三季度，迈威生物的归属净利润亏损6.941亿元。经计算，迈威生物上市后合计亏损金额超27亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217185536a1f59849&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217185536a1f59849&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399300","BK0239","159982","688062"],"gpt_icon":0},{"id":"2492609930","title":"亏损27亿元，Biotech龙头为激进买单","url":"https://stock-news.laohu8.com/highlight/detail?id=2492609930","media":"生物科技馆","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492609930?lang=zh_cn&edition=full","pubTime":"2024-12-17 11:31","pubTimestamp":1734406269,"startTime":"0","endTime":"0","summary":"然而，这一消息并未给市场带来太多惊喜，反而导致迈威生物的股价大幅下跌。然而，尽管手握巨额资金，迈威生物却并未能实现盈利。从财务数据来看，迈威生物的资金状况并不乐观。在此背景下，迈威生物再次募资的行为引发了市场的广泛关注。迈威生物此次在重庆投建的骨健康创新药项目，总投资额高达20亿元，其中公司出资不低于16亿元。然而，迈威生物要在这个领域站稳脚跟，仍需面临诸多挑战。这不禁让投资者为迈威生物的未来担忧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217113239ab7e0446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217113239ab7e0446&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239","399300","159982"],"gpt_icon":0},{"id":"2492609934","title":"迈威生物成立逾7年亏54亿现金吃紧 研发人员一年半缩水29%拟赴港IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2492609934","media":"长江商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492609934?lang=zh_cn&edition=full","pubTime":"2024-12-17 10:16","pubTimestamp":1734401817,"startTime":"0","endTime":"0","summary":"实际上，迈威生物从2017年成立开始，一直处于亏损状态。上市后，迈威生物营收持续增长，但亏损也越发严重。综合来看，迈威生物成立7年多来，公司净利润已累计亏损约54亿元。综合来看，近一年半来，迈威生物在职员工增加350人，涨幅约为33%；研发人员减少166人，降幅达29%。截至2024年三季度末，迈威生物货币资金达15.64亿元，短期借款和长期借款分别为9.08亿元和9.86亿元，公司现金开始吃紧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217102008a1f48afe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217102008a1f48afe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2492609936","title":"30多亿，不到3年就不够花了，创新药企赴港二次上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2492609936","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492609936?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:50","pubTimestamp":1734400200,"startTime":"0","endTime":"0","summary":"另外，12月16日，迈威生物宣布在重庆有合资总额20亿元的“迈威生物骨健康创新药”项目。今年以来，国家不断发布新规出手帮扶。4月19日，中国证券监督管理委员会发布了5项资本市场对港合作措施，支持内地龙头企业赴港上市；10月18日，香港证监会及香港交易所联合宣布将优化港股IPO审批流程。其中，预计市值不少于100亿港元的A股上市公司如果赴港上市，将享受快速审批通道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217095224ab7dcbf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217095224ab7dcbf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239","159992"],"gpt_icon":0},{"id":"2492398614","title":"筹划赴港上市 迈威生物还有盈利难题","url":"https://stock-news.laohu8.com/highlight/detail?id=2492398614","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492398614?lang=zh_cn&edition=full","pubTime":"2024-12-17 00:30","pubTimestamp":1734366606,"startTime":"0","endTime":"0","summary":"公告后股价大跌12月16日，迈威生物在披露两项重要举措后股价大跌，大幅收跌6.65%。拟投建骨健康创新药项目在宣布其赴港上市计划的同时，迈威生物还披露了一项投资计划，即拟投建骨健康创新药项目。面临扭亏难题不管是筹划赴港上市，还是重金投建骨健康创新药项目，或是迈威生物在业绩压力下作出的重要尝试。上市以来，迈威生物货币资金不断减少。截至今年三季度末，迈威生物账上货币资金余额为15.64亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217003012a1f3792c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217003012a1f3792c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2491615108","title":"上市三年持续亏损，迈威生物赶上了“A赴H”热潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2491615108","media":"猫财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491615108?lang=zh_cn&edition=full","pubTime":"2024-12-16 23:41","pubTimestamp":1734363694,"startTime":"0","endTime":"0","summary":"此次迈威生物官宣赴港，也赶上了A股上市公司赴港二次上市的大潮。12月16日，迈威生物股价低开低走。持续亏损，迈威生物计划赴港二次上市迈威生物成立于2017年，由青峰医药董事长唐春山创立，2022年1月在科创板上市。上市近三年后，迈威生物宣布将赴港上市。虽然已有产品上市，但目前迈威生物仍未摆脱亏损。长期亏损下，迈威生物的流动性压力逐渐增加。与此同时，多家生物医药公司也抛出了赴港上市计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216234213a1f3644d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216234213a1f3644d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2491552665","title":"“A+H”再升温，迈威生物拟赴港二次上市，前三季度亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2491552665","media":"时代周报-时代在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491552665?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:29","pubTimestamp":1734344940,"startTime":"0","endTime":"0","summary":"又一家A股医药上市公司宣布赴港二次上市。12月15日晚间，迈威生物公告称，拟在境外发行股份并在港交所主板上市，目前正与相关中介机构商讨，具体细节尚未确定，最终实施有重大不确定性。今年前三季度，迈威生物的归母净利润和扣非净利润分别为亏损6.94亿元、7.15亿元，相比上年同期，亏损额度均有扩大。截至今年三季度末，迈威生物账上的货币资金为15.64亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-16/doc-inczsfym5676781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2491961512","title":"迈威生物赴港融资与豪赌骨健康创新药：希望方舟还是风险暗礁？","url":"https://stock-news.laohu8.com/highlight/detail?id=2491961512","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491961512?lang=zh_cn&edition=full","pubTime":"2024-12-16 17:18","pubTimestamp":1734340680,"startTime":"0","endTime":"0","summary":"迈威生物公告表示正就发行H股并上市一事与中介机构展开商讨，具体细节尚未确定。“骨健康”创新药项目：前景未明的豪赌迈威生物与重庆方面合作的20亿元“骨健康”创新药项目同样充满风险。迈威生物的骨健康创新药能否突围成功上市，犹未可知。12月9日至12月13日，迈威生物股价下跌8.32%，位列创新药企业下跌前五。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216172336ab7bf01a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216172336ab7bf01a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688062"],"gpt_icon":0},{"id":"2491656774","title":"12月16日迈威生物-U跌6.65%，汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491656774","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491656774?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:08","pubTimestamp":1734336522,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日迈威生物-U跌6.65%，收盘报21.19元，换手率4.32%，成交量8.82万手，成交额1.87亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.38亿元，最新净值1.287，较上一交易日下跌2.05%，近一年下跌2.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121600019725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2491615128","title":"迈威生物披露两大重要消息，股价下跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491615128","media":"医药财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491615128?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:00","pubTimestamp":1734318058,"startTime":"0","endTime":"0","summary":"迈威生物于2022年1月18日在A股科创板上市。根据最新数据，迈威生物的A股总市值约为84亿元。然而根据迈威生物A股的股价表现来看，投资者似乎对该公司前往港交所募资以及与重庆合资新项目这两大消息并不看好。消息披露的翌日，公司股价大幅下跌，盘中跌幅超过7%。对于投资者而言，迈威生物的H股上市及骨健康创新药项目的投资带来了较大挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216111651ab7b36f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216111651ab7b36f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2491665831","title":"迈威生物拟赴港再上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2491665831","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491665831?lang=zh_cn&edition=full","pubTime":"2024-12-16 10:05","pubTimestamp":1734314700,"startTime":"0","endTime":"0","summary":"12月15日，迈威生物发布公告，为满足公司经营发展的资金需求，提升公司国际化水平，公司拟在境外发行股份（H股）并在香港联交所主板上市，公司将在股东大会决议有效期内选择适当的时机和发行窗口完成本次发行H股并上市。目前，迈威生物市值约90亿元，已拥有15个处于临床或上市阶段的核心品种，包括11个创新药和4个生物类似药，覆盖肿瘤、免疫、骨疾病、眼科、血液等多个重大疾病治疗领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-16/doc-inczrkux2783752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2491689446","title":"迈威生物-U创新低 9家券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2491689446","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491689446?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:40","pubTimestamp":1734313204,"startTime":"0","endTime":"0","summary":"12月16日，迈威生物-U股价大幅下跌，截至09点40分，迈威生物-U下跌5.02%，报21.56元/股，创近2个月新低，成交3360万元，换手率0.74%。资金动向截止发稿，迈威生物-U获得主力净流出543万元，其中超大单流出120万元，大单流出421万元。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。最新财报显示，今年三季报，迈威生物-U实现营业收入1.41亿元，同比增长41.79%，净利润为-6.94亿元，同比减少3.09%，基本每股收益为-1.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094014a1f1acf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094014a1f1acf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2491650577","title":"迈威生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2491650577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491650577?lang=zh_cn&edition=full","pubTime":"2024-12-16 04:51","pubTimestamp":1734295881,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日迈威（上海）生物科技股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来迈威（上海）生物科技股份有限公司新申请注册商标15件，截止目前公司共持有注册商标630件，另有111件商标尚在注册申请中。数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121600000595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2491571522","title":"迈威生物聘HAIWU为副总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2491571522","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491571522?lang=zh_cn&edition=full","pubTime":"2024-12-15 19:22","pubTimestamp":1734261720,"startTime":"0","endTime":"0","summary":"迈威生物发布关于聘任副总经理的公告。公司于2024年12月15日召开董事会，审议通过了聘任HAIWU（武海）为副总经理的议案，任期自董事会审议通过之日至董事会任期届满。HAIWU（武海）同时被提名为公司非独立董事候选人，任期待股东大会审议通过。他曾在多家生物科技公司担任重要职务，包括任职于Amgen和上海君实生物医药科技股份有限公司的副总经理等。2024年前三季度，迈威生物-U实现收入1.41亿元，归母净利润-6.94亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241215192927ab79af94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241215192927ab79af94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2491452257","title":"迈威生物预计2025年关联交易金额达2118万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491452257","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491452257?lang=zh_cn&edition=full","pubTime":"2024-12-15 19:21","pubTimestamp":1734261692,"startTime":"0","endTime":"0","summary":"迈威生物发布关于预计2025年度日常关联交易的公告。公司预计2025年度与关联方之间的日常关联交易金额为2118万元，其中房屋租赁预计金额为2000万元，占同类业务比例35.10%；房屋转租预计金额为45万元，占同类业务比例0.79%；向关联人采购固定资产和接受关联人提供的劳务各预计36万元。预计的关联交易基于公司正常的生产经营需要，且公司与关联方之间的合作关系较为稳定。文章来源：财中社迈威生物预计2025年关联交易金额达2118万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241215192907a1f059f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241215192907a1f059f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","stockEarnings":[{"period":"1week","weight":-0.0236},{"period":"1month","weight":-0.0755},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.3278},{"period":"1year","weight":-0.3103},{"period":"ytd","weight":-0.3671}],"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","perCapita":"14789股","boardName":"医药制造业","registeredCapital":"39960万元","compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1705},{"period":"6month","weight":0.1274},{"period":"1year","weight":0.1497},{"period":"ytd","weight":0.1265}],"survey":"　　迈威(上海)生物科技股份有限公司是一家创新型生物制药企业，主营业务为治疗用生物制品的研发、生产与销售，主要产品为抗体药物。截至本招股说明书签署日，新增授权专利4项，新增专利申请48项，独立承担1项国家“重大新药创制”重大科技专项，独立承担2项国家重点研发计划。","serverTime":1734991654868,"listedPrice":34.8,"stockholders":"13805人(较上一季度增加1.48%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}